ANAPTYSBIO, INC. Operating Cash Flow
ANAPTYSBIO, INC. (ANAB) reported Operating Cash Flow of -$52.56 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-09-21
- ANAPTYSBIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$26.64M.
- ANAPTYSBIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$25.92M.
- ANAPTYSBIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $98.00M.
- ANAPTYSBIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$27.36M.
- ANAPTYSBIO, INC. net cash provided by (used in) operating activities for fiscal 2025 was $19.70M.
- ANAPTYSBIO, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$135.34M.
- ANAPTYSBIO, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$120.80M.
- ANAPTYSBIO, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$73.59M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$26.64M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | -$52.56M 10-KT · filed 2026-09-21 | $45.44M derived: sum of 3 quarters · filed 2026-09-21 | $18.08M derived: sum of 4 quarters · filed 2026-09-21 |
| 2026-03-31 | -$25.92M 10-Q · filed 2026-05-12 | $72.08M derived: sum of 2 quarters · filed 2026-09-21 | $44.72M derived: sum of 3 quarters · filed 2026-09-21 | $4.48M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-12-31 | $98.00M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $70.64M derived: sum of 2 quarters · filed 2026-09-21 | $30.40M derived: sum of 3 quarters · filed 2026-09-21 | $19.70M 10-KT · filed 2026-09-21 |
| 2025-09-30 | -$27.36M derived: 10-Q 9 month − 10-KT 6 month · filed 2025-11-04 | -$67.60M derived: sum of 2 quarters · filed 2026-09-21 | -$78.30M 10-Q · filed 2025-11-04 | -$144.97M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-06-30 | -$40.24M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | -$50.94M 10-KT · filed 2026-09-21 | -$117.62M derived: sum of 3 quarters · filed 2026-09-21 | -$127.71M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-03-31 | -$10.70M 10-Q · filed 2026-05-12 | -$77.37M derived: sum of 2 quarters · filed 2026-09-21 | -$87.46M derived: sum of 3 quarters · filed 2026-09-21 | -$108.78M derived: sum of 4 quarters · filed 2026-09-21 |
| 2024-12-31 | -$66.67M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | -$76.76M derived: sum of 2 quarters · filed 2026-09-21 | -$98.08M derived: sum of 3 quarters · filed 2026-09-21 | -$135.34M 10-KT · filed 2026-09-21 |
| 2024-09-30 | -$10.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$31.41M derived: sum of 2 quarters · filed 2025-11-04 | -$68.67M 10-Q · filed 2025-11-04 | -$103.01M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | -$21.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$58.58M 10-Q · filed 2025-08-06 | -$92.92M derived: sum of 3 quarters · filed 2026-03-03 | -$129.40M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$37.25M 10-Q · filed 2025-05-05 | -$71.60M derived: sum of 2 quarters · filed 2026-03-03 | -$108.08M derived: sum of 3 quarters · filed 2026-03-03 | -$133.49M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | -$34.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$70.82M derived: sum of 2 quarters · filed 2026-03-03 | -$96.23M derived: sum of 3 quarters · filed 2026-03-03 | -$120.80M 10-K · filed 2026-03-03 |
| 2023-09-30 | -$36.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$61.88M derived: sum of 2 quarters · filed 2024-11-05 | -$86.45M 10-Q · filed 2024-11-05 | -$97.14M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$25.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$49.98M 10-Q · filed 2024-08-05 | -$60.66M derived: sum of 3 quarters · filed 2025-02-27 | -$78.41M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$24.57M 10-Q · filed 2024-05-09 | -$35.25M derived: sum of 2 quarters · filed 2025-02-27 | -$53.00M derived: sum of 3 quarters · filed 2025-02-27 | -$77.15M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$10.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$28.43M derived: sum of 2 quarters · filed 2025-02-27 | -$52.58M derived: sum of 3 quarters · filed 2025-02-27 | -$73.59M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$17.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$41.89M derived: sum of 2 quarters · filed 2023-11-02 | -$62.91M 10-Q · filed 2023-11-02 | -$88.21M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | -$24.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$45.16M 10-Q · filed 2023-08-07 | -$70.46M derived: sum of 3 quarters · filed 2024-03-11 | -$77.47M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | -$21.01M 10-Q · filed 2023-05-11 | -$46.31M derived: sum of 2 quarters · filed 2024-03-11 | -$53.32M derived: sum of 3 quarters · filed 2024-03-11 | -$43.73M derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | -$25.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$32.31M derived: sum of 2 quarters · filed 2024-03-11 | -$22.72M derived: sum of 3 quarters · filed 2024-03-11 | -$45.92M 10-K · filed 2024-03-11 |
| 2021-09-30 | -$7.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.58M derived: sum of 2 quarters · filed 2022-11-08 | -$20.62M 10-Q · filed 2022-11-08 | $16.96M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $9.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$13.61M 10-Q · filed 2022-08-08 | $23.96M derived: sum of 3 quarters · filed 2023-03-01 | $6.95M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$23.20M 10-Q · filed 2022-05-04 | $14.37M derived: sum of 2 quarters · filed 2023-03-01 | -$2.64M derived: sum of 3 quarters · filed 2023-03-01 | -$22.25M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $37.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $20.57M derived: sum of 2 quarters · filed 2023-03-01 | $955.00K derived: sum of 3 quarters · filed 2023-03-01 | -$14.16M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$17.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$36.62M derived: sum of 2 quarters · filed 2021-11-04 | -$51.73M 10-Q · filed 2021-11-04 | -$67.54M derived: sum of 4 quarters · filed 2022-03-07 |
| 2020-06-30 | -$19.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$34.72M 10-Q · filed 2021-08-09 | -$50.53M derived: sum of 3 quarters · filed 2022-03-07 | -$72.62M derived: sum of 4 quarters · filed 2022-03-07 |
| 2020-03-31 | -$15.11M 10-Q · filed 2021-05-04 | -$30.92M derived: sum of 2 quarters · filed 2022-03-07 | -$53.01M derived: sum of 3 quarters · filed 2022-03-07 | -$68.53M derived: sum of 4 quarters · filed 2022-03-07 |
| 2019-12-31 | -$15.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$37.90M derived: sum of 2 quarters · filed 2022-03-07 | -$53.42M derived: sum of 3 quarters · filed 2022-03-07 | -$69.52M 10-K · filed 2022-03-07 |
| 2019-09-30 | -$22.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$37.61M derived: sum of 2 quarters · filed 2020-11-04 | -$53.71M 10-Q · filed 2020-11-04 | -$66.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$15.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$31.62M 10-Q · filed 2020-08-10 | -$43.91M derived: sum of 3 quarters · filed 2021-02-25 | -$58.77M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$16.10M 10-Q · filed 2020-05-06 | -$28.39M derived: sum of 2 quarters · filed 2021-02-25 | -$43.25M derived: sum of 3 quarters · filed 2021-02-25 | -$52.13M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$12.29M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$27.15M derived: sum of 2 quarters · filed 2021-02-25 | -$36.03M derived: sum of 3 quarters · filed 2021-02-25 | -$48.51M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$14.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$23.74M derived: sum of 2 quarters · filed 2019-11-08 | -$36.22M 10-Q · filed 2019-11-08 | -$41.03M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$8.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$21.36M 10-Q · filed 2019-08-08 | -$26.17M derived: sum of 3 quarters · filed 2020-03-02 | -$30.05M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$12.48M 10-Q · filed 2019-05-07 | -$17.29M derived: sum of 2 quarters · filed 2020-03-02 | -$21.18M derived: sum of 3 quarters · filed 2020-03-02 | -$23.82M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | -$4.81M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$8.70M derived: sum of 2 quarters · filed 2020-03-02 | -$11.34M derived: sum of 3 quarters · filed 2020-03-02 | -$19.44M 10-K · filed 2020-03-02 |
| 2017-09-30 | -$3.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$6.53M derived: sum of 2 quarters · filed 2018-11-08 | -$14.63M 10-Q · filed 2018-11-08 | -$20.20M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | -$2.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$10.74M 10-Q · filed 2018-08-07 | -$16.31M derived: sum of 3 quarters · filed 2019-02-28 | -$19.38M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | -$8.10M 10-Q · filed 2018-05-08 | -$13.67M derived: sum of 2 quarters · filed 2019-02-28 | -$16.74M derived: sum of 3 quarters · filed 2019-02-28 | -$15.07M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | -$5.57M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$8.64M derived: sum of 2 quarters · filed 2019-02-28 | -$6.97M derived: sum of 3 quarters · filed 2019-02-28 | -$9.03M 10-K · filed 2019-02-28 |
| 2016-09-30 | -$3.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$1.40M derived: sum of 2 quarters · filed 2017-11-07 | -$3.46M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$387.00K 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | -$2.06M 10-Q · filed 2017-05-12 | |||
| 2015-12-31 | -$9.69M 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |